Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director · President and CEO | May 25, 2018 | May 29, 2018 |
| BullFrog AI Holdings, Inc.BFRG · Entity 8036 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date May 25, 2018 · Filed May 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 365,839 |
Reported balance
After 2018-05-25 transaction · row 1
1 source rowRow 1 · 2018-05-25 · Purchase · Acquired 1,300 · Balance 365,839 F1: The transaction was executed in multiple trades at prices ranging from $0.505151 to $0.5088. The price above reflects the weighted average purchase price. Detailed information regarding the number of shares purchased at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was executed in multiple trades at prices ranging from $0.505151 to $0.5088. The price above reflects the weighted average purchase price. Detailed information regarding the number of shares purchased at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
BullFrog AI Holdings, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 | Direct | 15,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 15,000 F3: The options were issued as a grant under the Plan, based on the market price on the date of the grant. F1: Represents stock options issued under BullFrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control. F2: The stock options expire on June 12, 2036. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options issued under BullFrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control.
F2: The stock options expire on June 12, 2036.
F3: The options were issued as a grant under the Plan, based on the market price on the date of the grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Barinthus Biotherapeutics plc.
Report date September 09, 2026 · Filed September 09, 2026
Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2026-09-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-09 · Disposition to issuer · Disposed 728,454 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). F4: Shares held by William J Enright TR UA Dated 03/04/2021 Enright Family 2021 Irrevocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2026-09-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-09 · Disposition to issuer · Disposed 514,923 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). F5: Shares held by William Enright Revocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-05-01 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-09 · Disposition to issuer · Disposed 176,130 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.12 · Expires 2032-03-14 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-09 · Disposition to issuer · Disposed 359,605 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-09 · Disposition to issuer · Disposed 440,000 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2034-01-02 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-09 · Disposition to issuer · Disposed 443,981 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-02-03 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-09 · Disposition to issuer · Disposed 600,000 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco.
F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock").
F4: Shares held by William J Enright TR UA Dated 03/04/2021 Enright Family 2021 Irrevocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.
F5: Shares held by William Enright Revocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any.
F6: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 9, 2026 20:18 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106336 · tm2625057-2_4seq1.xml · derivative · entry 7 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 600,000 shares Expires 2035-02-03 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:18 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 443,981 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001104659-26-106336 · tm2625057-2_4seq1.xml · derivative · entry 6 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 443,981 shares Expires 2034-01-02 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:18 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 440,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-26-106336 · tm2625057-2_4seq1.xml · derivative · entry 5 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 440,000 shares Expires 2033-01-03 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:18 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 359,605 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001104659-26-106336 · tm2625057-2_4seq1.xml · derivative · entry 4 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 359,605 shares Expires 2032-03-14 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:18 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerShare Option (Right to Buy) · Derivative | 176,130 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106336 · tm2625057-2_4seq1.xml · derivative · entry 3 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 176,130 shares Expires 2031-05-01 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:18 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerOrdinary Shares | 514,923 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-106336 · tm2625057-2_4seq1.xml · nonDerivative · entry 2 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3 · shares: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). F3 · price: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). F5 · ownership.nature: Shares held by William Enright Revocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 09, 2026 Filed Sep 9, 2026 20:18 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | Disposition to issuerOrdinary Shares | 728,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-106336 · tm2625057-2_4seq1.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3 · shares: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). F3 · price: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). F4 · ownership.nature: Shares held by William J Enright TR UA Dated 03/04/2021 Enright Family 2021 Irrevocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:29 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001493152-26-028743 · ownership.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · price: The options were issued as a grant under the Plan, based on the market price on the date of the grant. F1 · derivative.exercise_date: Represents stock options issued under BullFrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control. F2 · derivative.expiration_date: The stock options expire on June 12, 2036. Read SEC document |
| September 25, 2025 Filed Sep 30, 2025 00:14 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001493152-25-016099 · ownership.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · price: The options were issued as a grant under the Plan, based on the market price on the date of the grant. F1 · derivative.exercise_date: Represents stock options issued under Bullfrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), vesting on the earlier of September 25, 2026 and the date of the Company's annual meeting for fiscal year 2026. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing which may, or may not, constitute a change in control. F2 · derivative.expiration_date: The stock options expire on September 25, 2035. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:05 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-025526 · ownership.xml · nonDerivative · entry 2 Enright William · CIK 0001705564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,523 F2 · shares: Represents 2,813 shares of Common Stock issued as an equity grant under the Plan, fully vested upon grant. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:05 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantCommon Stock | 5,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-025526 · ownership.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,710 F1 · shares: Represents Restricted Stock Units ("RSUs") issued under the Company's 2022 Equity Compensation Plan (the "Plan"), vesting 50% on September 1, 2026, and the remaining 50% on September 1, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing which may, or may not, constitute a change in control. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:24 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001828185-25-000011 · wk-form4_1738790662.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Ordinary Shares · 600,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 26, 2024 Filed Feb 12, 2025 14:00 UTC | BullFrog AI Holdings, Inc. BFRG,BFRGW · Entity 8036 | GrantStock options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001493152-25-006046 · ownership.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common stock · 15,000 shares Expires not disclosed F1 · deemedExecutionDate: The options vest on September 26, 2025. F3 · price: The options were issued as a grant under the Company's equity incentive plan based on the market price on the date of the grant. F1 · derivative.exercise_date: The options vest on September 26, 2025. F2 · derivative.expiration_date: The options expire on September 26, 2034. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 13:54 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 443,981 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001104659-24-001165 · tm241766-2_4seq1.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,981 Underlying: Ordinary Shares · 443,981 shares Expires 2034-01-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 12:51 UTC | BullFrog AI Holdings, Inc. BFRG,BFRGW · Entity 8036 | PurchaseCommon Stock | 5,000 | $4.05 | $20,250.00 |
DisclosureSEC source: 0001493152-23-021350 · ownership.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · price: Mr. Enright purchased 5,000 of the Issuer's shares at a per share price of $4.05, for an aggregate purchase price of $20,250. Read SEC document |
| April 16, 2023 Filed May 9, 2023 21:26 UTC | BullFrog AI Holdings, Inc. BFRG,BFRGW · Entity 8036 | GrantStock options (Right to buy) · Derivative | 40,000 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001493152-23-015995 · ownership.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires not disclosed F1 · deemedExecutionDate: The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month. F1 · derivative.exercise_date: The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month. F2 · derivative.expiration_date: The option expires on April 16, 2033. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:41 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | SaleOrdinary Shares | 15,000 | $2.42 | $36,298.50 |
DisclosureSEC source: 0001104659-23-038357 · tm2310913-1_4seq1.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 728,454 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 - $2.47. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Shares held by William J Enright TR UA Dated 03/04/2021 Enright Family 2021 Irrevocable Trust, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by such trust for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 03, 2023 Filed Feb 23, 2023 21:55 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 440,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-23-024802 · tm237643-3_4seq1.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,000 Underlying: Ordinary Shares · 440,000 shares Expires 2033-01-03 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 03, 2022 Filed Feb 12, 2022 00:53 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 359,605 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001104659-22-020821 · tm226469-2_4seq1.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,605 Underlying: Ordinary Shares · 359,605 shares Expires 2032-01-03 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 04, 2021 Filed May 7, 2021 21:24 UTC Amendment | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantOrdinary Shares | 514,923 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-063196 · tm2115637-1_4aseq1.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,258,377 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The Reporting Person was previously granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 514,923 RSUs. F2 · price: The Reporting Person was previously granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 514,923 RSUs. Read SEC document |
| April 29, 2021 Filed May 5, 2021 00:24 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 176,130 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061223 · tm2114558-19_4seq1.xml · derivative · entry 2 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,130 Underlying: Ordinary Shares · 176,130 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 5, 2021 00:24 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantOrdinary Shares | 455,775 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-061223 · tm2114558-19_4seq1.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,199,229 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · kind: The Reporting Person was previously granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 455,775 RSUs. F2 · price: The Reporting Person was previously granted certain performance-based Restricted Share Units ("RSUs"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 455,775 RSUs. Read SEC document |
| May 25, 2018 Filed May 29, 2018 22:17 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 1,300 | $0.51 | $659.88 |
DisclosureSEC source: 0001012975-18-000467 · edgar.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,839 F1 · price: The transaction was executed in multiple trades at prices ranging from $0.505151 to $0.5088. The price above reflects the weighted average purchase price. Detailed information regarding the number of shares purchased at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer. Read SEC document |
| May 21, 2018 Filed May 23, 2018 21:21 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 103,158 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001012975-18-000455 · edgar.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,158 Underlying: Common Stock, par value $0.0001 · 103,158 shares Expires 2028-05-21 F1 · derivative.exercise_date: Twenty-five percent of the option becomes vested and exercisable on March 1, 2019, and the aggregate unvested remaining portion will vest and become exercisable in equal monthly installments on the first day of each month over the 36-month period starting April 1, 2019. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:53 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 183,347 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001012975-18-000025 · edgar.xml · derivative · entry 2 Enright William · CIK 0001705564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 183,347 shares Expires 2021-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:53 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 183,347 | $0.08 | $14,667.76 |
DisclosureSEC source: 0001012975-18-000025 · edgar.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 22:36 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 125,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001012975-17-000720 · edgar.xml · derivative · entry 1 Enright William · CIK 0001705564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock, par value $0.0001 · 125,000 shares Expires 2027-09-22 F1 · derivative.exercise_date: The option becomes exercisable, if at all, on March 31, 2019, in three equal one-third increments if the average daily closing price of Altimmune, Inc.'s common stock on Nasdaq for 10 consecutive trading days between September 22, 2017 and December 31, 2018 is at or above one of three specified thresholds, respectively. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 20:45 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 91,733 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001012975-17-000635 · edgar.xml · derivative · entry 4 Enright William · CIK 0001705564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,733 shares Expires 2021-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 20:45 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 71,644 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001012975-17-000635 · edgar.xml · derivative · entry 3 Enright William · CIK 0001705564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,644 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 20:45 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock | 91,733 | $0.08 | $7,338.64 |
DisclosureSEC source: 0001012975-17-000635 · edgar.xml · nonDerivative · entry 2 Enright William · CIK 0001705564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 20:45 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock | 71,644 | $0.08 | $5,731.52 |
DisclosureSEC source: 0001012975-17-000635 · edgar.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:32 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 99,927 | Not disclosed Strike: $6.50 | Not disclosed |
DisclosureSEC source: 0000899243-17-012357 · doc4.xml · derivative · entry 6 Enright William · CIK 0001705564 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,927 Underlying: Common Stock, par value $0.0001 · 99,927 shares Expires 2027-05-04 F4 · price: Granted under the terms of the Altimmune 2017 Omnibus Incentive Plan. F3 · derivative.exercise_date: On the first anniversary of the date of grant, 25% of the unvested portion of the option will become vested and exercisable, and the aggregate remaining unvested portion will vest and become exercisable in equal monthly installments over the 36-month period following such anniversary date. However, the agreement also provides that, if the compensation committee of the Issuer's board of directors, in its sole discretion, determines that the consummation of the mergers was successful, then 50% of the unvested portion of the option shall become immediately vested and exercisable. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:32 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 183,347 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012357 · doc4.xml · derivative · entry 5 Enright William · CIK 0001705564 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,347 Underlying: Common Stock, par value $0.0001 · 183,347 shares Expires 2021-12-03 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:32 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 91,733 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012357 · doc4.xml · derivative · entry 4 Enright William · CIK 0001705564 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,733 Underlying: Common Stock, par value $0.0001 · 91,733 shares Expires 2021-12-03 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:32 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 71,644 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012357 · doc4.xml · derivative · entry 3 Enright William · CIK 0001705564 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,644 Underlying: Common Stock, par value $0.0001 · 71,644 shares Expires 2019-12-31 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:32 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 125,887 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0000899243-17-012357 · doc4.xml · derivative · entry 2 Enright William · CIK 0001705564 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,887 Underlying: Common Stock, par value $0.0001 · 125,887 shares Expires 2018-05-31 F2 · price: Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:32 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 17,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-012357 · doc4.xml · nonDerivative · entry 1 Enright William · CIK 0001705564 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,787 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement, the then outstanding shares of Altimmune's capital stock was converted into the right to receive a number of shares of the Issuer's common stock, par value $0.0001 on a 0.749106:1 basis upon the closing of the merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.